10-K: OrthoPediatrics Reports Strong 2025 Revenue Growth Amid Losses

OrthoPediatrics Corp. announced a 15% revenue increase to $236.3 million in 2025, driven by core product performance and strategic acquisitions, despite continued operating losses.

Summary

• Net revenue increased 15% to $236.3 million for the year ended December 31, 2025, up from $204.7 million in 2024.
• The company reported a net loss of $39.6 million in 2025, an increase from the $37.8 million net loss in 2024.
• Operating loss for 2025 was $39.2 million, compared to $35.0 million in 2024.
• Trauma and deformity revenue grew 15% to $166.3 million, accounting for 70% of total revenue.
• Scoliosis revenue increased 20% to $66.0 million, representing 28% of total revenue.
• Sports medicine/other revenue decreased 10% to $4.0 million, making up 2% of total revenue.
• Gross margin remained stable at 73% for both 2025 and 2024.
• Accumulated deficit as of December 31, 2025, reached $275.2 million.
• Cash, cash equivalents, and restricted cash totaled $21.6 million as of December 31, 2025.
• The company operates 87 surgical and bracing systems, serving an estimated $6.2 billion global pediatric orthopedic market.
• Acquired multiple orthotic and prosthetic (O&P) clinics in North Carolina, Colorado, New York, Florida, Connecticut, and Ireland in 2025.
• Established a legal entity in Brazil in November 2025 to facilitate direct sales and distribution.
• The FIREFLY Technology license agreement was amended and extended until 2030, and the 7D Surgical FLASH Navigation platform license was extended through 2028.
• Launched the GIRO Growth Modulation System in 2025 and beta-launched VerteGlide in Q3 2025 after receiving FDA regulatory clearance.
• Restructuring expenses of $5.6 million were recorded in 2025, including a $1.9 million goodwill write-off related to the Telos business exit.
• Intangible asset impairment charges totaled $4.6 million in 2025, primarily affecting ApiFix, MedTech, Orthex, and Telos trademarks.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed filing. While revenue growth is strong in core segments and strategic expansion continues, the increasing net and operating losses, significant impairment charges, and ongoing restructuring expenses indicate underlying profitability challenges and strategic adjustments that temper the positive operational performance.

Positives

• Strong revenue growth of 15% year-over-year, reaching $236.3 million in 2025.
• Significant growth in core product categories: Trauma and Deformity revenue increased 15%, and Scoliosis revenue increased 20%.
• Strategic international expansion with the establishment of a legal entity in Brazil and new warehouses in the Netherlands, Germany, and Australia.
• Continued inorganic growth through acquisitions of O&P clinics in multiple U.S. states and Ireland, and a clubfoot bracing manufacturer in the UK.
• Robust product pipeline with new launches like the GIRO Growth Modulation System and the beta launch of VerteGlide, alongside ongoing development of the 3P platform and next-generation scoliosis fusion systems.
• Received FDA Breakthrough Device designation for Active Growing Implants (eLLi), indicating innovative technology recognition.
• Achieved MDR certification on December 10, 2025, ensuring continued access to the European Economic Area market.
• Demonstrated commitment to clinical education and research, being a leading financial contributor to pediatric orthopedic surgical societies.
• Recognized for nine consecutive years as one of the 'Best Companies to Work in Indiana', reflecting a positive corporate culture.

Negatives

• Continued operating losses of $39.2 million in 2025, following $35.0 million in 2024, indicating ongoing challenges to achieve profitability.
• Net loss increased to $39.6 million in 2025 from $37.8 million in 2024.
• Sports medicine/other revenue decreased by 10% in 2025.
• Significant intangible asset impairment charges of $4.6 million in 2025, primarily due to lower forecasted revenue for ApiFix, MedTech, Orthex, and the exit from the Telos business.
• Restructuring expenses increased to $5.6 million in 2025, including a goodwill write-off, reflecting ongoing cost-cutting measures and business adjustments.
• Negative cash flow from operating activities of $4.9 million in 2025, indicating reliance on financing for operations.
• The company has an accumulated deficit of $275.2 million as of December 31, 2025.
• Reliance on a small number of third-party contract manufacturers and suppliers poses supply chain risks.
• Lack of published long-term data supporting superior clinical outcomes for products, which could limit sales and market acceptance.
• Exposure to unfavorable economic conditions such as prolonged inflation, rising interest rates, or a recession, which could adversely affect financial results.

Risks

• Inability to predict the extent to which widespread health emergencies, such as COVID-19 and respiratory syncytial virus (RSV), or other pandemics, epidemics, and infectious disease outbreaks, may adversely impact business and financial results.
• Unfavorable economic conditions such as prolonged inflation, rising interest rates, or a recession could adversely affect business, financial condition, or results of operations.
• Incurred losses in the past and may be unable to achieve or sustain profitability in the future.
• May be unable to generate sufficient revenue from the commercialization of products to achieve profitability.
• May need to raise additional capital to fund existing commercial operations, develop and commercialize new products, and expand operations.
• Long-term growth depends on the ability to commercialize products in development and to develop and commercialize additional products through research and development efforts; failure to do so may prevent effective competition.
• Lack of published long-term data supporting superior clinical outcomes by products, which could limit sales.
• If coverage and reimbursement from third-party payors for procedures using products significantly decline, orthopedic surgeons, hospitals, and other healthcare providers may be reluctant to use products, and sales may decline.
• May be unable to successfully demonstrate to orthopedic surgeons the merits of products compared to those of competitors.
• Products and operations are subject to extensive government regulation and oversight both in the United States and abroad; failure to comply with applicable requirements, including HDE and IRB regulations, could harm business.
• Reliance on a network of third-party independent sales agencies and distributors; inability to maintain and expand this network may prevent generation of anticipated sales.
• Inability to adequately protect intellectual property rights or accusations of infringing on the intellectual property rights of others could harm competitive position or require significant expenses.
• Integration risks from significant future acquisitions.
• Risks of doing business in other countries, including those related to tariffs, trade restrictions, and government actions.
• Changes in Medicaid coverage and reimbursement policies may adversely affect business, financial condition, and results of operations.
• Potential significant political, trade, or regulatory developments may impact business.
• Sales volumes and results of operations may fluctuate over the course of the year.
• Loan and security agreement with Braidwell LP contains covenants that may restrict business and financing activities.
• Effective tax rate may fluctuate, and obligations in tax jurisdictions may exceed accrued amounts.
• Ability to use net operating losses to offset future taxable income may be subject to limitations under Section 382 of the Internal Revenue Code.
• Goodwill, intangible assets, and fixed assets are subject to potential impairment; additional charges may be required.
• If the quality of products does not meet the expectations of physicians or patients, brand and reputation could suffer.
• Inability to compete successfully against existing or potential competitors.
• Maintaining sufficient levels of inventory (implant and instrument sets) could consume significant resources, reduce cash flows, and lead to inventory impairment charges.
• The provision of loaned instrument sets to customers may implicate certain federal and state fraud and abuse laws.
• Inability to gain the support of leading hospitals and key opinion leaders, which may make it difficult to establish products as a standard of care and achieve market acceptance.
• Inability to maintain adequate working relationships with healthcare professionals.
• If orthopedic surgeons fail to safely and appropriately use products, or if unable to train orthopedic surgeons on safe and appropriate use, expected growth may not be achieved.
• Business is subject to seasonal fluctuations.
• Inability to convince hospital facilities to approve the use of products, which may decrease sales.
• Inability to successfully expand sales infrastructure and adequately address customer needs could negatively impact sales and market acceptance.
• Loss of senior management or inability to attract and retain highly skilled salespeople and engineers could negatively impact business.
• Negatively impacted by restructuring initiatives, including execution risk, employee morale, costs, operational disruptions, and regulatory compliance risks.
• Risks associated with international business, including compliance with the U.S. Foreign Corrupt Practices Act (FCPA) and foreign currency exchange rate fluctuations.
• Incur significant costs as a result of operating as a public company, and management is required to devote substantial time to public company compliance programs.
• Failure to maintain proper and effective internal controls over financial reporting may adversely affect investor confidence.
• Significant disruptions in information technology systems, including cybersecurity threats and risks from artificial intelligence-based systems, may adversely affect business.
• May be subject to various litigation claims and legal proceedings, such as the IMED Surgical software ownership dispute.
• Product liability lawsuits could harm business and may require payment of damages that exceed insurance coverage.
• Operations are vulnerable to interruption or loss due to natural or other disasters, power loss, strikes, and other events beyond control.
• Failure to timely obtain necessary clearances or approvals for future products would adversely affect the ability to grow business.
• Modifications to products may require new 510(k) clearances or PMA approvals, potentially leading to marketing cessation or recalls.
• Products must be manufactured in accordance with federal and state regulations; failure to comply could force recalls or terminate production.
• Misuse or off-label use of products may harm reputation, result in injuries, or lead to costly investigations, fines, or sanctions.
• Products may cause or contribute to adverse medical events that are required to be reported to regulatory authorities; failure to do so would subject the company to sanctions.
• Inability to obtain and maintain international regulatory registrations or approvals for products.
• Legislative or regulatory reforms in the United States, the United Kingdom, or the European Union may make it more difficult and costly to obtain regulatory clearances or approvals.
• Healthcare policy changes, including recently enacted legislation reforming the U.S. healthcare system, could harm cash flows, financial condition, and results of operations.
• Business involves the use of hazardous materials, and compliance with environmental laws and regulations may be expensive and restrict how business is conducted.
• The proliferation of physician-owned distributorships could result in increased pricing pressure on products or harm the ability to sell products.
• Conversion of the Convertible Notes will dilute the ownership interest of existing stockholders or may otherwise depress the price of common stock.
• Provisions in the indenture governing the Convertible Notes could delay or prevent an otherwise beneficial takeover.
• The price of common stock may be volatile.
• The price of stock may be vulnerable to manipulation, including through short sales.
• May be subject to securities litigation, which is expensive and could divert management's attention.
• Future sales of common stock may cause stock price to decline.
• If there is no viable public market for common stock, investors may be unable to sell shares.
• Operating results for a particular period may fluctuate significantly or may fall below the expectations of investors or securities analysts.
• Principal stockholders and management own a significant percentage of stock and will be able to exert control over matters subject to stockholder approval.
• Provisions of charter documents or Delaware law could delay or prevent an acquisition of the company, even if beneficial to stockholders.
• No cash dividends anticipated on common stock in the foreseeable future; capital appreciation, if any, will be the sole source of gain.
• If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about business, stock price and trading volume could decline.

Future Outlook

The company expects to continue incurring significant product development, clinical and regulatory, sales and marketing, and other expenses, anticipating continued losses in the near term as it expands its product portfolio and invests in additional consigned implant and instrument sets. It aims to launch at least one new surgical system and multiple product line extensions in its trauma and deformity and scoliosis businesses, as well as 4-5 new specialty bracing products each year for the foreseeable future. The company is nearing final development of its Active Growing Implants (eLLi) and expects a full-scale launch of VerteGlide in 2026, with a next-generation scoliosis fusion system expected in Q4 2026.

Management Comments

• We believe we should continue to expand our social impact, create an inclusive culture, and ensure good corporate governance practices.
• We expect to continue to increase our disclosures and communicate our social impact efforts in future SEC filings.
• We believe our higher corporate purpose captures the imagination of our employees and makes them committed to doing everything better, faster and at lower cost.
• We believe effectively managing our priorities, as well as increasing our transparency related to social impact programs, will help create long-term value for our stakeholders.
• We believe our current facilities are suitable and adequate to meet our current needs. We may add new facilities or expand existing facilities as we add employees, and we believe suitable additional or substitute space will be available as needed to accommodate any such expansion of our operations.

Industry Context

StockSavvy.ai notes that OrthoPediatrics Corp. maintains a unique position as the only global medical device company exclusively focused on the pediatric orthopedic market, which it estimates to be a $6.2 billion global opportunity. The company's strategy of designing and commercializing anatomically appropriate implants and specialized bracing directly addresses a historical neglect of this patient population by the broader orthopedic industry, which often repurposes adult implants. Its focus on high-volume children's hospitals and deep engagement with pediatric orthopedic surgeons through product development and clinical education helps solidify its category leadership against larger, more diversified competitors like Johnson & Johnson MedTech, Medtronic plc, and Smith & Nephew plc, who primarily target the adult market. The company's continued investment in R&D and strategic acquisitions further reinforces its specialized market position.

Comparison to Industry Standards

• OrthoPediatrics Corp. is the only global medical device company focused exclusively on pediatric orthopedics, differentiating it from major competitors like Johnson & Johnson MedTech, Medtronic plc, and Smith & Nephew plc, which primarily serve the broader adult orthopedic market.
• The company's comprehensive portfolio of 87 surgical and bracing systems specifically designed for children contrasts with the limited age-specific offerings typically available from general orthopedic companies.
• OrthoPediatrics' estimated addressable market of $6.2 billion globally ($2.8 billion in the U.S.) for pediatric orthopedics highlights a specialized niche compared to the much larger overall orthopedic market served by diversified players.
• The company's commitment to clinical education and research, being a leading financial contributor to five primary pediatric orthopedic surgical societies, demonstrates a deeper engagement with its specialized surgeon community than typically seen from generalist competitors.
• The company's strategy of increasing investment in consigned implant and instrument sets in high-volume children's hospitals aims to accelerate market penetration efficiently, a model tailored to the concentrated nature of pediatric orthopedic procedures, unlike the broader distribution strategies of larger competitors.

Management Changes

Corporate Governance

Legal Proceedings

• IMED Surgical Software Ownership Dispute: IMED Surgical, LLC claims ownership of U.S. Patent No. 10,258,377 ('Point and click alignment method for orthopedic surgeons') used by OrthoPediatrics, Orthex, and Squadron. The lawsuit was stayed pending arbitration, which IMED re-initiated in September 2024 after a court dismissal for failure to prosecute. The company believes it has strong defenses, but an adverse resolution could materially affect its business, operating results, and financial condition.

Related Party Transactions

• Mortgage note payable to Tawani Enterprises Inc. (an affiliate of Squadron, the company's largest investor) for office and warehouse space, with monthly principal and interest installments of $16 and 5% interest until maturity in August 2028. The mortgage balance was $453 as of December 31, 2025.
• Purchases from Structure Medical, LLC (a Squadron-affiliated entity) for inventory components totaled $1,931 in 2025, $1,006 in 2024, and $1,060 in 2023.

Stakeholder Impact

• Shareholders: Face potential dilution from the conversion of convertible notes and future capital raises. The stock price may experience volatility due to market factors and company performance. Anti-takeover provisions in charter documents may limit opportunities for premium acquisition offers. No cash dividends are anticipated in the foreseeable future, making capital appreciation the sole source of gain.
• Employees: Impacted by restructuring initiatives and workforce reductions, which may affect morale and retention. Benefit from the OrthoPediatrics 401(k) Retirement Plan with company matching contributions. The company emphasizes an inclusive culture and has been recognized as a 'Best Company to Work in Indiana'.
• Customers (Hospitals, Surgeons, Patients): Benefit from the company's comprehensive pediatric orthopedic product offerings and O&P clinic services. Potential impact from product quality issues, regulatory changes, or declines in third-party reimbursement for procedures using the company's products.
• Suppliers: The company relies on a limited number of third-party contract manufacturers and suppliers, creating a risk of supply disruptions or increased costs if these relationships are compromised.
• Creditors: Subject to financial and non-financial covenants outlined in the Term Loan Agreement with Braidwell LP, which restrict certain business and financing activities. Failure to comply could lead to acceleration of debt obligations.

Next Steps

• Continue to expand social impact, create an inclusive culture, and ensure good corporate governance practices.
• Increase disclosures and communicate social impact efforts in future SEC filings.
• Expand product offering to address additional categories of the pediatric orthopedic market, such as active growing implants for early onset scoliosis and limb length discrepancies.
• Expand product offering within current categories (trauma and deformity, scoliosis, sports medicine/other) and address new categories like craniomaxillofacial, upper extremity, pediatric orthopedic oncology, pelvis, and other sports-related injuries.
• Aspire to launch at least one new surgical system and multiple product line extensions in trauma and deformity and scoliosis businesses each year.
• Aspire to launch 4-5 new specialty bracing products each year.
• Full-scale launch of VerteGlide is expected in 2026.
• Launch of the 3P Small/Mini system is expected in the first half of 2026, followed by additional 3P systems throughout 2027-2028.
• Launch of the next-generation scoliosis fusion system is expected in Q4 2026.
• Continue to seek partnership and select acquisition opportunities that expand the total available market and serve new unmet needs in pediatric orthopedics.
• Deepen partnership with surgeons by expanding clinical education programs and partnerships with teaching hospitals, sponsoring surgical workshops for residents and fellows, and supporting clinical research projects.
• Continue to add products to the MDR certificate to support identified product sales in the EEA.
• Further development of the external fixation portfolio will continue to focus on hardware and software upgrades, as well as a completely new system for emergency fracture management and deformity osteotomy stabilization.
• Continue to monitor risks related to the restructuring plan and take appropriate measures to mitigate their impact.
• Continue to monitor the dynamic of RSV season and its potential impact on sales volume.
• May consider raising additional capital in the future to expand the business, pursue strategic investments, or for other reasons.
• Will continue to evaluate and deploy artificial intelligence-based information technology systems in certain aspects of operations.
• The VP of Information Technology will continue to provide regular reports on ongoing cybersecurity risk and mitigation practices to the COO and CFO, who then report to the Board.
• The Board will continue to consider cybersecurity risks in business strategy by getting updates on cybersecurity risk assessment.
• On February 1, 2026, the company acquired London Orthotic Consultancy Consolidated Ltd (LOC) and its subsidiaries, with potential earnout payments and future restricted stock awards to sellers and an employee.

Key Dates

Recommendation

OrthoPediatrics Corp. demonstrates strong revenue growth in its core pediatric orthopedic segments and is actively expanding its market reach through strategic acquisitions and product development. However, the persistent operating losses, increasing net loss, significant intangible asset impairments, and ongoing restructuring expenses indicate that the company is still in a heavy investment phase with profitability challenges. The recent capital raise through convertible notes and term loans provides liquidity but also introduces potential future dilution. Given the strong market position and growth initiatives balanced against the current lack of profitability and associated risks, a 'hold' recommendation is appropriate for investors to monitor the execution of its growth strategy and progress towards sustainable profitability.

Keywords

pediatric orthopedics, medical devices, trauma and deformity correction, scoliosis, orthotic and prosthetic, O&P clinics, implants, braces, surgical systems, FDA clearance, SEC filing, 10-K, OrthoPediatrics, KIDS Nasdaq, financial results, revenue growth, net loss, capital stock, corporate governance, risk factors, intellectual property, acquisitions, restructuring, convertible notes, Braidwell LP, ApiFix, Boston Brace, VerteGlide, GIRO